Cyclomed pitch @user-pe6tl7wd9v at Expo2020 Dubai Spanish Pavillion 3-Feb-2022

13 Dec 2022 · 4 min

Watch on YouTube

3:49

In this pitch delivered at Expo2020 Dubai, the presenter outlines Cyclomed (also referred to as Saigon), a Spanish deep‑tech spin‑off that emerged from the CDTI‑funded national project AMIT (Advanced Molecular Imaging Techniques). The company was created in 2019 by partners including the research centre DMAC and private investor Maydega (Fundación Botín) to commercialise technologies developed in AMIT. The team is presented, highlighting strong technical expertise (José Manuel Pérez – head of technology, Luis García Tavares – head of electrical engineering) and business development experience (Juan José Marcos Carrillo), as well as advisory board members from Spain’s startup ecosystem. The pitch then frames the societal problem: an ageing population has shifted mortality from infectious to chronic, degenerative diseases, creating a demand for personalized medicine. Molecular imaging—specifically nuclear‑medicine modalities PET and SPECT that rely on radioisotopes—is positioned as essential for delivering patient‑specific therapies. The presenter sets the stage to explain how Cyclomed’s innovative products will address this need.

Chapters

Allow me to take this down because I'm terrible with the microphone. So first, allow me to thank the organizers. Isabel, and I want to thank you for taking the time to be here, and I want to, uh, desire that you take the most out of it. Um, so, Saigon, we are a Spanish deep tech company focused in developing innovative products and bringing them to market. Um, to understand the nature of our company, let me go a bit back. Our project started in within a national collaboration funded by CDTI in a project that was called AMIT, which means Advanced Molecular Imaging Techniques, that was launched to improve or to overcome the limitations of our country in these molecular imaging techniques. In 2019, some partners of the company of This project, such as DMAC, a research center and a private company, created a spin-off with the aid of a private investor, Maydega, from Fundación Botín, to exploit the technology developed during the project. Now allow me to introduce some members of the team. We come with a strong technical expertise. With José Manuel Pérez, the head of technology of FEMAC, Luis García Tavares, the head of the electrical engineering division, and we also have a strong entrepreneurship and business development experience with Juan José Marcos Carrillo. And on the other side of this slide, you can see my colleagues Pedro and Iván, and myself with probably a much better face actually due to the jet lag. And we are so proud to have, um, as partners of the company, the researchers and scientists that participate in the, in the initial project. And we also come with a strong advisory board with us, experience in the startup ecosystem of Spain. Now, before going to what we do, uh, let me explain why we do it. There is obvious concern In modern society, about the aging of the population, the causes of death have shifted in the last 50 years from infectious diseases to degenerative and chronic diseases. And to overcome this type of illness and to combat this type of illness, we need for personalized medicine and a specific treatment for each individual patient. Here, medical imaging techniques are essential. Since they provide a powerful tool to medical doctors to provide the adequate therapy to each patient. And among medical imaging techniques, let me highlight those related to the nuclear medicine area, which are called PET and SPECT, that need of radioisotopes to produce visibilities. So now let me talk about